PR Newswire Clinical TrialsOriginal article
Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004
AST-004Positive
AI Analysis
Summary
Astrocyte Pharmaceuticals secured $9.5 million in Series B funding to advance Phase 2 development of AST-004 for traumatic brain injury and concussion treatment. Enrollment is complete in the STARFAST sports-related concussion trial with topline results expected in winter 2026.
Clinical Trial Data
Phase
Phase 2
Outcome Details
$9.5 Million Series B funding secured
Importance:7/10
Sentiment:
0.75
Series B FundingPhase 2 DevelopmentCerebroprotective TherapyTBIConcussionClinical Trial Enrollment CompleteBreakthrough Designation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 30, 2026 10:00 AM